Hepatocellular Carcinoma | Specialty

EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC

July 19th 2024

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.

NMPA Accepts sNDA for Toripalimab Plus Bevacizumab as Frontline Therapy in Advanced HCC

July 18th 2024

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

NDA Resubmission Planned for Rivoceranib/Camrelizumab in Unresectable HCC Following FDA CRL

July 9th 2024

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Dr Franses on the Feasibility of Co-Inhibiting Angiogenesis and PD-1 Pathways in HCC

June 28th 2024

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Dr El-Khoueiry on Regorafenib/Pembrolizumab in Advanced HCC After Prior Anti–PD-1/L1 Therapy

June 24th 2024

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

June 24th 2024

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Frontline Camrelizumab/Rivoceranib Prolongs OS vs Sorafenib in Unresectable HCC

June 11th 2024

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

June 2nd 2024

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC

May 30th 2024

Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

May 27th 2024

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

ASCO Updates Advanced HCC Treatment Guideline

April 29th 2024

ASCO has announced a guideline update for systemic therapy in advanced hepatocellular carcinoma.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

April 23rd 2024

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Locoregional Therapies for Intermediate-Stage HCC

April 23rd 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC

April 17th 2024

Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular carcinoma.

HCC Staging: Improving Treatment Strategies

April 16th 2024

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

Examining the Role of Liver Function in HCC

April 16th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Trajectory of Evolving HCC Treatment Landscape

April 15th 2024

The expert panelists provide their final insights surrounding the future of HCC treatment management.

REGONEXT Study: Driving Second-line HCC Treatment Strategy

April 15th 2024

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

April 8th 2024

Key opinion leaders share their takeaways from the CARES-310 trial and its impact on their treatment approach in HCC management.